DOCSLIB.ORG

2020 Marketing Code of Conduct Compliant Companies

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Nevada State Board of Pharmacy 2020 Marketing Code of Conduct Compliant Companies Pursuant to NRS 639.570 Published 11-2-2020 2020 Nevada Marketing Code of Conduct Compliant Companies Manufacturers and Wholesalers Address City ST Zip Submitted under Company Name: Companies, Affiliated Companies or Subsidiaries included on compliance form Abbott Electrophysiology and Heart Failure Abbott Laboratories Abbott Cardiac Rhythm Management Abbott Laboratories Abbott Cardiovascular and Neuromodulation Abbott Laboratories Abbott Diabetes Care Division Abbott Laboratories Abbott Diagnostic Division Abbott Laboratories Abbott Laboratories 100 Abbott Park Road, Dept. EC10, Bldg. APGA-2 Abbott Park IL 60064 Abbott Laboratories Abbott Molecular Division Abbott Laboratories Abbott Neuromodulation Abbott Laboratories Abbott Nutrition Products Division Abbott Laboratories Abbott Point of Care Division Abbott Laboratories Abbott Rapid Diagnostics Abbott Laboratories Abbott Structural Heart Abbott Laboratories Abbott Vascular Division Abbott Laboratories AbbVie, Inc. 1 N. Waukegan Road North Chicago IL 60064 AbbVie, Inc. Acadia Pharmaceuticals, Inc. 3611 Valley Centre Drive, Suite 300 San Diego CA 92130 Acadia Pharmaceuticals, Inc Acclarent, Inc. 33 Technology Drive Irvine CA 92618 Acclarent, Inc. Accuri Cyometers, Inc. Becton Dickinson and Company Accutron, Inc Cantel Medical Corp. Ace Surgical Supply, Inc. 1034 Pearl St. Brockton MA 02301 Ace Surgical Supply, Inc. Acell, Inc. 6640 Eli Whitney Drive, Suite 200 Columbia MD 21046 Acell, Inc. Acera Surgical, Inc 10880 Baur Blvd St Louis MO 63132 Acera Surgical, Inc Aclaris Therapeutics, Inc. 640 Lee Road, Suite 200 Wayne PA 19087 Aclaris Therapeutics, Inc. Acorda Therapeutics, Inc. 420 Sawmill River Road Ardsley NY 10502 Acorda Therapeutics, Inc. Johnson & Johnson Pharmaceutical Actelion Pharmaceuticals US, Inc. Affiliates Adamas Pharma, LLC Adamas Pharmaceuticals, Inc. Adamas Pharmaceuticals, Inc. 1900 Powell Street, Suite 1000 Emeryville CA 94608 Adamas Pharmaceuticals, Inc. Adaptive Biotechnologies Corporation 1551 Eastlake Avenue East, Ste 200 Seattle WA 98102 Adaptive Biotechnologies Corporation A-Dec Inc 2601 Crestview Drive Newberg OR 97132 A-Dec Inc Adlon TherapeuticsLP Purdue Pharma LP Advanced Accelerator Applications USA, Inc. 57 E Willow Street Millburn NJ 07041 Advanced Accelerator Applications USA, Inc. Advanced Respiratory, Inc. Hill-Rom Holdings, Inc. Page 1 of 17 Published 11/2/2020 Advanced Sterilization Products Services, Advanced Sterilization Products Services, Inc. 6920 Seaway Boulevard Everett WA 98203 Inc. Aegerion Pharmaceuticals. Inc. (Amryt) 245 First Street, 18th Floor Cambridge MA 02142 Aegerion Pharmaceuticals. Inc. (Amryt) Aerie Pharmaceuticals, Inc. 550 Hills Drive, 3rd Floor Bedminster NJ 07921 Aerie Pharmaceuticals, Inc. Aesculap Implant Systems, Inc. 3773 Corporate Parkway Center Valley PA 18034 Aesculap Implant Systems, Inc. Aesculap, Inc. 3773 Corporate Parkway Center Valley PA 18034 Aesculap, Inc. Afaxys Pharma, LLC PO Box 20639 Charleston SC 29413 Afaxys Pharma, LLC Aimmune Therapeutics, Inc. 8000 Marina Blvd. Suite 300 Brisbane CA 94005 Aimmune Therapeutics, Inc. Agios Pharmaceuticals, Inc. 88 Sydney St Cambridge MA 02139 Agios Pharmaceuticals, Inc. Akcea Therapeutics, Inc. 22 Boston Wharf Road Boston MA 02210 Akcea Therapeutics, Inc. Akebia Therapeutics, Inc. 245 First Street, Suite 1400 Cambridge MA 02142 Akebia Therapeutics, Inc. Alamo Pharma Services, Inc. Mission Pharmacal Company Alcon Vision 6201 South Freeway Fort Worth TX 76134 Alcon Vision Alden Optical Laboratories, Inc. Bausch Health US, Inc. Aldenex Vision LLC Bausch Health US, Inc. Alexion Pharmaceuticals, Inc 121 Seaport Boulevard Boston MA 02210 Alexion Pharmaceuticals, Inc ALK-Abello, Inc 1700 Royston Lane Round Rock TX 78664 ALK-Abello, Inc Alkermes, Inc. 852 Winter Street Waltham MA 02451 Alkermes, Inc. Allen Medical Systems, Inc. 825 Winter Waltham MA 02461 Hill-Rom Holdings, Inc. Allergan, PLC 5 Giralda Farms Madison NJ 07940 Allergan, PLC Almirall, LLC 707 Eagleview Blvd Ste 200 Exton PA 19341 Almirall, LLC Alnylam Pharmaceuticals 300 Third Street Cambridge MA 02142 Alnylam Pharmaceuticals Alverix, Inc. Becton Dickinson and Company AMAG Pharma USA 1099 Winter Street, Suite 3000 Waltham MA 02451 AMAG Pharmaceuticals, Inc. AMAG Pharmaceuticals, Inc. 1100 Winter Street Waltham MA 02451 AMAG Pharmaceuticals, Inc. Amarin Pharma, Inc. 440 Route 22, Suite 300 bridgewater NJ 08807 Amarin Pharma, Inc. AMATECH Corporation Hill-Rom Holdings, Inc. American Regent Daiichi Sankyo, Inc Amerisource Health Services Corp (dba American 2550 John Glenn Ave, Suite A Columbus OH 43217 AmerisourceBergen Corporation Health Packaging) AmerisourceBergen Corporation 1300 Morris Drive Chesterbrook PA 19087 AmerisourceBergen Corporation AmerisourceBergen Drug Corporation AmerisourceBergen Corporation AMF Support Surfaces, Inc. Hill-Rom Holdings, Inc. Amgen, Inc. 1 Amgen Center Drive Thousand Oaks CA 91320 Amgen, Inc. Amicus Therapeutics, Inc. 1 Cedarbrook Drive Cranbury NJ 08512 Amicus Therapeutics, Inc. Amneal Pharmaceuticals 400 Crossing Blvd, 3rd floor Bridgewater NJ 08807 Amneal Pharmaceuticals Anodyne Medical Devices, Inc. Hill-Rom Holdings, Inc. Apetvo BioTherapeutics Medexus Pharma, Inc. Apollo Endosurgery, Inc. 1120 S Capital of TX Hwy, Bldg 1, ste 300 Austin TX 78746 Apollo Endosurgery, Inc. Rancho Santa Applied Medical Distribution Corporation 22872 Avenida Empress CA 92688 Applied Medical Resources Corporation Margarita Applied Manufacturing, LLC Applied Medical Resources Corporation Page 2 of 17 Published 11/2/2020 Rancho Santa Applied Medical Resources Corporation 22872 Avenida Empresa CA 92688 Applied Medical Resources Corporation Margarita Apria Healthcare, Inc 26220 Enterprise Court Lake Forest CA 92630 Apria Healthcare, Inc Aquestive Therapeutics 30 Technology Drive Warren NJ 07059 Aquestive Therapeutics Aribex, Inc. 1717 West Collins Avenue Orange CA 92867 Aribex, Inc. Arkis Biosciences Inc. Integra LifeSciences Corporation Arkray America, Inc 5182 W. 76th St Minneapolis MN 55439 Arkray America, Inc Arkray Factory USA, Inc Arkray America, Inc Arkray USA, Inc Arkray America, Inc Arrow International, Inc Teleflex Incorporated Arrow Interventional, Inc Teleflex Incorporated Arthrex, Inc. 1370 Creekside Blvd Naples FL 34108 Arthrex, Inc. Ascension Orthopedics, Inc. Integra LifeSciences Corporation ASD Specialty Healthcare, Inc.(dba Besse Medical AmerisourceBergen Corporation and Oncology Supply) Assertio Therapeutics, Inc. 100 S. Saunders Dr, Ste 300 Lake Forest IL 60045 Assertio Therapeutics, Inc. Astellas Pharma US, Inc. One Astellas Way Northbrook IL 60062 Astellas Pharma US, Inc. AstraZeneca LP 1800 Concord Pike Wilmington DE 19850 AstraZeneca Pharmaceuticals LP AstraZeneca Pharmaceuticals LP 1800 Concord Pike Wilmington DE 19850 AstraZeneca Pharmaceuticals LP Astute Medical, Inc. 3550 General Atomics Court, Bldg. 2 San Diego CA 92121 BioMerieux Inc AtriCure, Inc. 7555 Innovation Way Mason OH 45040 AtriCure, Inc. Audrey Enterprise, LLC Bausch Health US, Inc. Auris Health, Inc. Ethicon Inc. Avanir Pharmaceuticals, Inc. 30 Enterprise, Suite 200 Aliso Viejo CA 92656 Avanir Pharmaceuticals, Inc. Avedro, Inc. Glaukos Corporation Averitas Pharma Inc. GRT US Holdings. Inc Avexis, Inc., a Novartis Company 2275 Half Day Road, Suite 300 Bannockburn IL 60015 Avexis, Inc., a Novartis Company Avid Radiopharmaceuticals, Inc. Eli Lilly and Company AVITA Medical Americas, LLC 28159 Avenue Stanford Ste 220 Valencia CA 91355 AVITA Medical Americas, LLC Avrio Health L.P. (formerly Purdue Products LP) One Stamford Forum / 201 Tresser Blvd. Stamford CT 06901 Purdue Pharma LP Axonics Modulation Technologies, Inc. 26 Technology Drive Irvine CA 92618 Axonics Modulation Technologies, Inc. AYTU BioScience, Inc. 373 Inverness Parkway, Suite 206 Englewood CO 80112 AYTU BioScience Inc. B&B Pharmaceuticals, Inc. 8591 Prairie Train Drive, Ste C-600 Englewood CO 80112 B&B Pharmaceuticals, Inc. B. Braun Interventional Systems, Inc. 824 12th Avenue Bethlehem PA 18018 B. Braun Interventional Systems, Inc. B. Braun Medical, Inc. 824 12th Avenue Bethlehem PA 18018 B. Braun Medical, Inc. Bard Access Systems, Inc. C.R. Bard, Inc. Bard Medical Division C.R. Bard, Inc. Bard Peripheral Vascular, Inc. C.R. Bard, Inc. Bausch & Lomb Incorporated Bausch Health US, Inc. Bausch & Lomb South Asia, Inc. Bausch Health US, Inc. Bausch Foundation LLC Bausch Health US, Inc. Bausch Health Americas, Inc. Bausch Health US, Inc. Bausch Health US, Inc. 400 Somerset Corporate Boulevard Bridgewater NJ 08807 Bausch Health US, Inc. Page 3 of 17 Published 11/2/2020 Bausch Health US, LLC Bausch Health US, Inc. Baxter Healthcare Corporation One Baxter Parkway Deerfield IL 60015 Baxter Healthcare Corporation Bayer Consumer Health Division Bayer US, LLC Bayer Crop Science, Animal Health Business Bayer US, LLC Bayer Healthcare Pharmaceuticals, Inc. Bayer US, LLC Bayer US, LLC 100 Bayer Boulevard, PO 915 Whippany NJ 07981 Bayer US, LLC BD Biosciences Sys & Reagents, Inc. Becton Dickinson and Company BD Infusion Therapy Systems, Inc. Becton Dickinson and Company Beckman Coulter, Inc. 250 S. Kraemer Boulevard Brea CA 92821 Beckman Coulter, Inc. Becton Dickinson and Company (BD) and 1 Becton Drive Franklin Lakes NJ 07417 Becton Dickinson and Company subsidiaries Biocomp Pharma, Inc. Mission Pharmacal Company BioDelivery Sciences International, Inc. 3141 ParkLake Avenue, Suite 225 Raleigh NC 27612 BioDelivery Sciences International, Inc. Biogen Inc 225 Binney Street
Recommended publications
  • Fully Human Domain Antibody Therapeutics: the Best of Both Worlds

    Fully Human Domain Antibody Therapeutics: the Best of Both Worlds

    Drug Discovery Fully Human Domain Antibody Therapeutics: The Best of Both Worlds By combining the therapeutic benefits of small molecule drugs with those of fully human antibodies, Domain Antibodies are expected to have strong therapeutic and commercial potential. By Robert Connelly at Domantis Robert Connelly is Chief Executive Officer of Domantis. He has over 22 years’ commercial experience of the life science sector, including that gained in the fields of diagnostics, drug discovery technologies and antibody therapeutics. Prior to joining Domantis, he was CEO of Veritas Pharmaceuticals (Los Angeles, USA), an in vivo imaging start-up company. He spent over five years with IGEN International, latterly as Senior Vice President and General Manager, Life Sciences, where he took part in the company’s IPO and financing rounds, raising $130 million. The first 11 years of his career were spent at Abbott Laboratories in sales, marketing and management positions. Domain Antibodies (dAbs) are the smallest functional variable regions of either the heavy (VH) or light (VL) binding units of antibodies. At Domantis, we are chains of human antibodies. Domantis scientists applying our proprietary know-how in dAbs to deliver have used the variable domains sequences of human human therapies that address large, unmet medical antibodies to create a series of large and highly needs in areas such as inflammation, cancer and functional libraries of fully human dAbs, with each autoimmune diseases. Three and a half years after library comprising at least 1010 different dAbs. The opening our laboratories, we have a dozen proprietary dAbs selected from these libraries are both specific therapeutic programmes underway, and an additional for their biological target and are well folded and eight therapeutic programmes with partners.
  • Faculty Disclosure

    Faculty Disclosure

    Faculty Disclosure In accordance with the ACCME Standards for Commercial Support, course directors, planning committees, faculty and all others in control of the educational content of the CME activity must disclose all relevant financial relationships with any commercial interest that they or their spouse/partner may have had within the past 12 months. If an individual refuses to disclose relevant financial relationships, they will be disqualified from being a part of the planning and implementation of this CME activity. Owners and/or employees of a commercial interest with business lines or products relating to the content of the CME activity will not be permitted to participate in the planning or execution of any accredited activity. Nature of Relevant Financial Relationship Last Name Commercial Interest What Was Received For What Role AbbVie, Allergan/ Tobira Therapeutics Inc, Gilead Research Grant Research Balart Sciences Inc, Pfizer, Salix Pharmaceuticals AbbVie, Merck Honorarium Advisory Board Bau None N/A N/A Benz None N/A N/A AbbVie, Arbutus Biopharma, Dieterich Gilead Sciences, Inc., Bristol- Research Grant Consultant Myers Squibb, Merck Bayer HealthCare Pharmaceuticals, Gilead Sciences Honorarium Speaking, Consultant Inc. Bristol-Myers Squibb, Gilead Speaking, Advisory Sciences, Inc, Salix Honorarium Frenette Board Pharmaceuticals, Inc, Merck Intercept Pharmaceuticals Honorarium Advisor Conatus Pharmaceuticals Inc Honorarium Consulting Principle Investigator, Research Grant, Han Gilead Sciences,
  • Health Advisory

    Health Advisory

    Health Advisory July 2, 2021 • Information for Pierce County Healthcare Providers Communicable Disease Control Communicable Disease Control • (253) 649-1412 3629 S. D St. • Tacoma, WA 98418 (253) 649-1412 • (253) 649-1358 (fax) COVID-19 Updates for Providers Requested actions • Be aware Washington State Department of Health (DOH) issued a behavioral health provider alert about Fourth of July celebrations and other summertime gatherings. The alert asks providers to give patients information about safe social behaviors and the potential negative effects of impulsive behaviors following the state’s full reopening and the misperception that the COVID-19 pandemic has ended. • Be aware the U.S. Food and Drug Administration (FDA) updated the following Emergency Use Authorization (EUA) fact sheets to include the possible risk of pericarditis and myocarditis following vaccination: o Pfizer fact sheet for healthcare providers. o Pfizer fact sheet for patients. o Moderna fact sheet for healthcare providers. o Moderna fact sheet for patients. • Continue to report any case of myocarditis and pericarditis among people who received COVID-19 mRNA vaccine within the last 2 weeks. o Promptly report cases to the U.S. Vaccine Adverse Events Reporting System (VAERS). o Report cases to the Health Department’s 24-hour reporting line at (253) 649-1413. Include vaccine manufacturer, vaccine lot number, vaccination date, dose number, patient gender, age and history of prior SARS-CoV-2 infection. • Be aware the FDA extended the shelf life of Janssen (Johnson & Johnson) COVID-19 vaccine from 3 months to 4½ months. Visit Janssen’s lot expiry checker to determine the updated expiration of your vaccine.
  • 1 UNITED STATES DISTRICT COURT DISTRICT of MINNESOTA Shirley

    1 UNITED STATES DISTRICT COURT DISTRICT of MINNESOTA Shirley

    CASE 0:10-cv-01821-JNE-JJK Document 65 Filed 04/05/11 Page 1 of 5 UNITED STATES DISTRICT COURT DISTRICT OF MINNESOTA Shirley Venus Shannon, Plaintiff, v. Civil No. 10-1821 (JNE/JJK) ORDER Baxter Healthcare Corporation, Hospira, Inc., and Abbott Laboratories, Inc., Defendants. In April 2010, Shirley Venus Shannon brought this action against Eli Lilly & Company and several unidentified entities. In October 2010, she filed an Amended Complaint against Baxter Healthcare Corporation, Hospira, Inc., and Abbott Laboratories, Inc. Abbott Laboratories and Hospira moved to dismiss the case for improper venue, see Fed. R. Civ. P. 12(b)(3); moved to dismiss the case for failure to state a claim upon which relief can be granted, see Fed. R. Civ. P. 12(b)(6); and moved to transfer the case to the United States District Court for the Northern District of Illinois, Eastern Division, see 28 U.S.C. § 1404(a) (2006). After answering, Baxter Healthcare joined the motions of Abbott Laboratories and Hospira. Baxter Healthcare did not separately submit memoranda of law. Shannon opposed the motions, but she asserted that the case should be transferred to the United States District Court for the Western District of Tennessee, Western Division. For the reasons set forth below, the Court transfers this action to the Western District of Tennessee. The Court first considers whether this case should be dismissed for improper venue. See Fed. R. Civ. P. 12(b)(3). The defendant bears the burden of establishing improper venue. United States v. Orshek, 164 F.2d 741, 742 (8th Cir.
  • Manufacturers and Wholesalers Street

    Manufacturers and Wholesalers Street

    Nevada AB128 Code of Conduct Compliant Companies Manufacturers and Wholesalers Street City ST Zip 10 Edison Street LLC 13 Edison Street LLC Abbott Diabetes Care Division Abbott Diagnostic Division Abbott Electrophysiology (including Kalila Medical 2- 2016)) Abbott Laboratories 100 Abbott Park Road, Dept. EC10, Bldg. APGA-2 Abbott Park IL 60064 Abbott Medical Optics Abbott Molecular Division Abbott Nutrition Products Division Abbott Vascular Division (includes Tendyne 9-2015) AbbVie, Inc. 1 N. Waukegan Road North Chicago IL 60064 Acadia Phamaceuticals 3611 Valley Centre Drive, Suite 300 San Diego CA 92130 Accelero Health Partners, LLC Acclarent, Inc. 1525-B O'Brien Dr. Menlo Park CA 94025 Accuri Cyometers, Inc. Ace Surgical Supply, Inc. 1034 Pearl St. Brockton MA 02301 Acorda Therapeutics, Inc. 420 Sawmill River Road Ardsley NY 10532 AcriVet, Inc. Actavis W.C. Holding, Inc. Morris Corporate Center III, 400 Interpace Parkway Parsippany NJ 07054 Actavis , Inc. Actelion Pharmaceuticals US, Inc. 5000 Shoreline Court, Suite 200 S. San Francisco CA 94080 Activis 400 Interpace parkway Parsippany NJ 07054 A-Dec, Inc. 2601 Crestview Dr. Newberg OR 97132 Advanced Respiratory, Inc. Advanced Sterilization Products 33 Technology Drive Irvine CA 92618 Advanced Vision Research, Inc., dba Akorn Consumer Health Aegerion Pharmaceuticals, Inc. 101 Main Street, Suite 1850 Cambridge MA 02142 Aesculap Implant Systems, Inc. Aesculap, Inc. 3773 Corporate Parkway Center Valley PA 18034 Aesthera Corporation Afaxys, Inc. PO Box 20158 Charleston SC 29413 AGMS, Inc. Akorn (New Jersey) Inc. Page 1 of 23 Pages 2/15/2017 Nevada AB128 Code of Conduct Compliant Companies Akorn AG (formerly Excelvision AG) Akorn Animal Health, Inc.
  • United States Court of Appeals for The

    United States Court of Appeals for The

    Case 14-4353, Document 100-1, 05/16/2016, 1772362, Page1 of 37 14‐4353‐cv Apotex Inc., et al., v. Acorda Therapeutics, Inc. UNITED STATES COURT OF APPEALS FOR THE SECOND CIRCUIT August Term, 2015 (Argued: November 12, 2015 Decided: May 16, 2016) Docket No. 14‐4353‐cv ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐x APOTEX INC., et al., Plaintiffs‐Appellants, ‐ v.‐ ACORDA THERAPEUTICS, INC., Defendant‐Appellee. ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐x Before: JACOBS, LIVINGSTON and DRONEY, Circuit Judges. This appeal concerns two distinct questions: the circumstances under which the filing of a citizen petition with the Food and Drug Administration provides grounds for an antitrust claim, and the scope of false advertising Case 14-4353, Document 100-1, 05/16/2016, 1772362, Page2 of 37 liability under the Lanham Act. Plaintiffs Apotex Incorporated and Apotex Corporation appeal from the judgment of the United States District Court for the Southern District of New York (Swain, J.) that granted defendant Acorda Therapeutics, Inc.’s motion to dismiss plaintiffs’ Sherman Act claim and that granted summary judgment in favor of defendant on the Lanham Act claims (Torres, J.). Because each of these conclusions was sound, we affirm. KEITH D. PARR (with Joseph N. Froehlich, Scott B. Feder, Hugh S. Balsam, James T. Peterka, and Andy J. Miller on the brief), Locke Lord LLP, Chicago, Illinois, for Appellants Apotex Incorporated & Apotex Corporation. JOHN W. NIELDS, JR. (with Jason C. Raofield and Colin P. Watson on the brief), Covington & Burling LLP, Washington, D.C. for Appellee Acorda Therapeutics, Inc. DENNIS JACOBS, Circuit Judge: The parties are rival manufacturers of tizanidine, a drug for treating spasticity.
  • Abbott-Abbvie Multiple Employer Pension Plan

    Abbott-Abbvie Multiple Employer Pension Plan

    Abbott-AbbVie Multiple Employer Pension Plan Summary Plan Description Effective January 1, 2013 This summary plan description (SPD) describes the key features of the Abbott-AbbVie Multiple Employer Pension Plan effective January 1, 2013. This booklet describes only the highlights of the plan and does not attempt to cover all administrative details. Every attempt has been made to communicate this information clearly and in easily understandable terms. Benefits and services described here apply only to those former employees and retirees eligible for benefits under the plan. The boards of directors of the companies, or when applicable, the Abbott-AbbVie Pension Plan Administrative Committee, reserve the right to modify, suspend or terminate these benefits at any time to the extent permitted by law. This SPD does not constitute a contract of employment or guarantee any particular benefit. The terms of the Abbott-AbbVie Multiple Employer Pension Plan are governed by the plan and trust documents. In case of a conflict between this SPD and those documents, the plan and trust documents will control. Table of Contents Introduction................................................................................................................................................. 1 Eligibility ..................................................................................................................................................... 1 Eligible Employees ................................................................................................................................
  • Q1 Pharma Sector Snapshot

    Q1 Pharma Sector Snapshot

    SPECIALTY & GENERIC PHARMA Q1 2021 Report Market Commentary – Debt Capital Markets Debt Markets ▪ 2020 saw increased amounts of debt used in buyouts across the board, resulting in the highest debt / EBITDA Median US Buyout Multiples levels since 2014 − The increased use of debt was driven by 2H20 back- end loaded lending activity (primarily 4Q20) as 16.0x 12.7x 14.1x 12.2x 12.0x 11.6x 11.5x certainty around the U.S. election and vaccination 11.1x 10.0x 9.8x 12.0x 9.7x expectations increased 9.4x 8.6x 8.3x 8.2x 7.5x 7.8x 5.2x 6.7x 5.7x 5.6x ▪ 8.0x 5.9x As the effects of COVID now begin to diminish, debt 5.4x 4.4x 4.1x 3.7x 4.6x 4.3x 3.8x markets have seemingly recovered, signaling that 3.6x lenders have become increasingly comfortable with 4.0x 4.3x 6.9x 6.5x 6.3x 6.0x 5.9x 5.7x 5.7x 5.7x 5.7x 5.6x 5.3x 4.5x 4.4x macroeconomic and company-specific fundamentals 4.3x 0.0x 3.2x − With increased confidence, lenders are currently looking to provide strong leverage for high-quality assets, particularly ones that have proven their Debt/EBITDA Equity/EBITDA EV/EBITDA stability through the recent market downturn Source: PitchBook ▪ The spread on U.S. high-yield debt has returned to pre- Historical US High Yield Debt Effective Yield COVID levels − 4.22% current effective yield compared with a 12.0% 11.4% 11.38% effective yield on March 23, 2020 (peak of the pandemic) 9.0% ▪ We expect increased activity by lenders in 2021 due to: 6.0% 4.2% − Pent-up demand in M&A activity driven by the impact of COVID 3.0% − Limited Partner agreements and investor
  • Eli Lilly and Company

    Eli Lilly and Company

    Merrimack College Merrimack ScholarWorks Honors Senior Capstone Projects Honors Program Spring 2021 Eli Lilly and Company Alyssa Ardai Follow this and additional works at: https://scholarworks.merrimack.edu/honors_capstones Part of the Business Commons Ardai 1 Written Assignment #4 Eli Lilly and Company Alyssa Ardai Bus 4402W: Strategic Analysis and Decision Making Professor Herrmann April 30, 2021 Ardai 2 Abstract Eli Lilly and Company is a pharmaceutical company that has the goal of creating new products. Eli Lilly’s products are seen in hospitals and pharmacies around the US, with the hopes of growing internationally. By having a large number of drugs in their pipeline, they can be a key player in improving multiple types of illnesses as well as help aid the aging population. The healthcare sector is always one that is high-performing. Ardai 3 Eli Lilly and Company is positioned as a pharmaceutical company, with the goal of creating high-quality medicine for every need or to take a preexisting medicine and make it better. For the past 140 years, they have been creating medicine for various causes, but are now focusing their efforts on antibody treatments for the COVID-19 pandemic, as well as different cancers and autoimmune diseases. Everything that the company does should follow its core values: integrity, excellence, and respect for people (Eli Lilly and Company - A). Eli Lilly is found in the US, Japan, Europe, and hopes to expand to the rest of the world soon. They are broken down into Endocrinology, Oncology, Immunology, Neuroscience, & Other. The company has increased revenues from $23,832.8 - $25,925.3, a consistent tax rate of 15%, expenses increasing $300k a year, accounts receivable, or a/r, decreasing as they pay less in patents and drugs go generic, consistent inventory of $120k - $140k, showing they do not keep a lot on hand, a weighted average cost of capital, or WACC, of 5.9% showing it does not hold a lot of debt, and a long term growth rate of 2.3%, showing a healthy but stable growth (Bloomberg LP, CapitalIQ 2021).
  • Market Cap Close ADV

    Market Cap Close ADV

    Market Cap Close ADV 1598 67th Pctl $745,214,477.91 $23.96 225,966.94 801 33rd Pctl $199,581,478.89 $10.09 53,054.83 2399 Listing_ Revised Ticker_Symbol Security_Name Exchange Effective_Date Mkt Cap Close ADV Stratum Stratum AAC AAC Holdings, Inc. N 20160906 M M M M-M-M M-M-M Altisource Asset Management AAMC Corp A 20160906 L M L L-M-L L-M-L AAN Aarons Inc N 20160906 H H H H-H-H H-H-H AAV Advantage Oil & Gas Ltd N 20160906 H L M H-L-M H-M-M AB Alliance Bernstein Holding L P N 20160906 H M M H-M-M H-M-M ABG Asbury Automotive Group Inc N 20160906 H H H H-H-H H-H-H ABM ABM Industries Inc. N 20160906 H H H H-H-H H-H-H AC Associated Capital Group, Inc. N 20160906 H H L H-H-L H-H-L ACCO ACCO Brand Corp. N 20160906 H L H H-L-H H-L-H ACU Acme United A 20160906 L M L L-M-L L-M-L ACY AeroCentury Corp A 20160906 L L L L-L-L L-L-L ADK Adcare Health System A 20160906 L L L L-L-L L-L-L ADPT Adeptus Health Inc. N 20160906 M H H M-H-H M-H-H AE Adams Res Energy Inc A 20160906 L H L L-H-L L-H-L American Equity Inv Life Hldg AEL Co N 20160906 H M H H-M-H H-M-H AF Astoria Financial Corporation N 20160906 H M H H-M-H H-M-H AGM Fed Agricul Mtg Clc Non Voting N 20160906 M H M M-H-M M-H-M AGM A Fed Agricultural Mtg Cla Voting N 20160906 L H L L-H-L L-H-L AGRO Adecoagro S A N 20160906 H L H H-L-H H-L-H AGX Argan Inc N 20160906 M H M M-H-M M-H-M AHC A H Belo Corp N 20160906 L L L L-L-L L-L-L ASPEN Insurance Holding AHL Limited N 20160906 H H H H-H-H H-H-H AHS AMN Healthcare Services Inc.
  • COVID-19 Treatment and Vaccine Tracker This Document Contains an Aggregation of Publicly Available Information from Validated Sources

    COVID-19 Treatment and Vaccine Tracker This Document Contains an Aggregation of Publicly Available Information from Validated Sources

    COVID-19 Treatment and Vaccine Tracker This document contains an aggregation of publicly available information from validated sources. It is not an endorsement of one approach or treatment over another but simply a list of all treatments and vaccines currently in development. TREATMENTS Current Type of FDA-Approved Clinical Trials for Funding Clinical Trials for Anticipated Next Number Developer/Researcher Stage of Published Results Sources Product - Treatment Indications Other Diseases Sources COVID-19 Steps Timing Development ANTIBODIES PhRMA Begin Phase 1 trials in late Polyclonal hyperimmune Alliance among Takeda, CSL Behring, Wall Street Journal spring. To patients between 1 globulin (H-IG), formerly N/A Biotest AG, Bio Products Laboratory, Pre-clinical Pink Sheet December 2020 and December known at TAK-888 LFB, and Octapharma Press release from the 2021 alliance Biomedical Stat News Advanced MarketWatch Antibodies from mice, Research and Reuters 2 REGN3048-3051, against the N/A Regeneron Pre-clinical Start Phase 1 June 2020 Development Bloomberg News spike protein Authority FierceBiotech (BARDA) FiercePharma Korea Herald Antibodies from recovered 3 N/A Celltrion Pre-clinical Start Phase 1 in July 2020 UPI COVID-19 patients Celltrion press release Super-antibody or antibody 4 cocktail to target potential N/A Celltrion Pre-clinical Celltrion press release mutations of SARS-CoV-2 Antibodies from recovered BioSpace 5 N/A Kamada Pre-clinical COVID-19 patients AbbVie Stat News Antibodies from recovered 6 N/A Vir Biotech/WuXi Biologics/Biogen Pre-clinical Start Phase 1 ~ July 2020 Vir Biotech COVID-19 patients Vir Biotech * Indicates updated or new field This document contains an aggregation of publicly available information from validated sources.
  • Ipo Analysis

    Ipo Analysis

    IPO ANALYSIS Snap Research on potential upcoming IPOs from Hamilton Lane Bitcoin Investment Trust selected candidate companies. Visterra Braeburn Pharmaceuticals December, 2016 VentureDeal Snap Files S-1 Registration For $3 Billion IPO Quick Take Camera company Snap Inc. (Pending:SNAP) has filed its initial S-1 registration for a $3 billion IPO at an undisclosed valuation. Snap views the camera as the primary use of the mobile device and seeks to monetize its user base primarily through advertising. The company has a short history of rapidly growing revenues, which exceeded $400 million in 2016. Company Venice-based Snap was founded in 2012 by current CEO Evan Spiegel and current CTO Robert Murphy to initially provide users with a smartphone app that enabled them to post pictures that were automatically deleted after a brief time period. The company has since expanded its scope to include chat, video, media that does not become automatically deleted, and a camera integrated into sunglasses. Below is a brief company video on its recently introduced Spectacles product: (Source: Snap YouTube) Snap has raised in excess of $2.6 billion in several private financing rounds from numerous investors including top tier venture capital firms, corporate investors, private equity firms and government-owned investment enterprises. The company claims that 158 million people use its flagship Snapchat each day, creating over 2.5 billion 'Snaps'. Market and Competition Snap operates a largely advertising-driven business model, although it does sell its Spectacles product for $129 each. It seeks to provide advertisers with access to its user base, which has typically centered around a younger demographic, between the ages of 14-30.